Shanghai, China, 14 February 2025 – MicroPort® CardioFlow is proud to announce that its second-generation transcatheter aortic valve implantation (TAVI) solution, VitaFlow Liberty® Transcatheter Aortic Valve and Retrievable Delivery System (VitaFlow Liberty®), has received marketing approval from the Central Drugs Standard Control Organization (CDSCO) of India (License No.: IMP/MD/2024/000964).
VitaFlow Liberty® inherits the advantages of its predecessor, VitaFlow®, in terms of valve design, featuring a hybrid density self-expanding stent, bovine pericardial leaflets, and an advanced double-layer PET skirt. These design elements offer strong radial support, improved coaxial deployment, and reduced perivalvular leakage post-procedure. Moreover, its breakthrough next-generation delivery system incorporates a unique and innovative double-reinforced spiral structure that ensures rapid, stable, and precise release and retrieval. This system also provides flexibility, allowing for 360-degree bending of the valve segment.
As the world’s only electric retrievable TAVI (Transcatheter Aortic Valve Implantation）system, VitaFlow Liberty®, along with its accessory, the Alwide® series Balloon Catheter, has been successfully adopted in over 700 leading hospitals across 20 countries and regions, benefiting over 10,000 patients with aortic valve diseases worldwide.
India’s TAVI market reached 3,000 units in 2024 and is expected to grow significantly. The approval of VitaFlow Liberty® is set to enhance the surgical experience for Indian physicians through its innovative technology, potentially reshaping the competitive landscape of the country’s TAVI market. This milestone also marks a significant step in MicroPort® CardioFlow’s expansion into the Asian market, bringing new hope to patients with structural heart diseases.
About MicroPort® CardioFlow
Founded in 2015, MicroPort® CardioFlow (MicroPort® CardioFlow Medtech Corporation; HKEX: 02160) is a leading medical device company focusing on research, development and commercialization of innovative transcatheter and surgical solutions for structural heart disease.
MicroPort® CardioFlow’s self-developed transcatheter aortic valve implantation series products are successfully used in more than 700 core hospitals worldwide. In addition, MicroPort® CardioFlow has established a strategic Research and Development pipeline covering TAVI (transcatheter aortic valve treatment) products, left atrial appendage closure systems, transcatheter mitral valve treatment products, transcatheter tricuspid valve treatment products, and surgical accessories through in-house development and collaboration with global partners. MicroPort® CardioFlow is committed to providing total solutions for structural heart diseases, delivering high-quality therapeutic solutions to patients and physicians across the globe.
More information is available at www.en.cardioflowmedtech.com